Advertisement

Borrelia burgdorferi as a risk factor for Alzheimer’s dementia and mild cognitive impairment

  • Alejandro Herrera-Landero
  • Luis Enrique Amaya-Sánchez
  • Carlos d´Hyver de las-Deses
  • Fortino Solórzano-Santos
  • María Guadalupe Gordillo-Pérez
Research Paper
  • 7 Downloads

Abstract

Objective

To determine the association of Borrelia burgdorferi infection with Alzheimer’s disease or mild cognitive impairment (MCI) in older adults.

Methods

Case–control study. Patients older than 60 years, both sexes, were included. Three groups were created: with probable Alzheimer’s disease cases with NINCDS–ADRDA criteria, MCI cases in those not meeting NINCDS–ADRDA criteria for dementia, but who had an abnormal cognitive evaluation and independence in instrumental activities of daily living (IADL), cognitively healthy controls were diagnosed with normal cognitive evaluation and independence in IADL were identified in the community. Western blot IgG against B. burgdorferi in serum was done in all the participants. Non-conditional logistic regression was applied to estimate the association of Alzheimer’s disease or MCI and seropositive to B. burgdorferi.

Results

Thirty-eight patients with Alzheimer’s disease, mean age of 75.6 ± 3.4 years, 69% were females, education 8.3 ± 4.8 years. 39 patients with MCI, mean age of 72.2 ± 6.8 years, 85% were females, education 11.2 ± 4.2 years. A total of 11/38 (29%) were positive to B. burgdorferi with Alzheimer’s disease, 9/39 (23%) with MCI, and 11/108 (10%) of controls. In patients with Alzheimer’s disease, an adjusted odds ratio (aOR) = 3.65 (95% CI 1.2–11.1) adjusted for education and a history of cerebrovascular disease (CVD) was estimated, and in patients with MCI an aOR = 3.2 (95% CI 1.1–9.1) for a history of diabetes mellitus and CVD was estimated.

Conclusions

In our study, there was an increased risk of Alzheimer’s disease and MCI in seropositive IgG patients to B. burgdorferi.

Key Summary Points

Aim

Establish if Borrelia burgdorferi infection is associated with Alzheimer's disease and/or mild cognitive impairment (MCI) in older adults.

Findings

In patients with Borrelia burgdorferi infection and Alzheimer's disease, an adjusted Odds Ratio (AOR) = 3.65 (95% CI = 1.2−11.1) was estimated, which was similar to that of patients with Borrelia burgdorferi infection and MCI with an AOR = 3.2 (95% CI = 1.1−9.1).

Message

In our study, there was an increased risk of Alzheimer's disease and MCI in seropositive IgG patients to B. burgdorferi.

Keywords

Aged Alzheimer disease Borrelia burgdorferi Lyme disease Mild cognitive impairment 

Notes

Acknowledgements

We express our gratitude and acknowledge the important contributions of the participants and staff of the National Institute of Adult Older Persons Cultural Centers.

Funding

This work was supported by the Instituto Mexicano del Seguro Social (FIS/IMSS Prot MD17/1688) and Universidad Nacional Autónoma de Mexico (Support Program for Graduate Studies 2017). The funder did not influence the design, methods, subject recruitment, data collections, analysis or preparation of the paper.

Compliance with ethical standards

Conflict of interest

The authors have no financial or any other kind of personal conflicts with this paper.

Ethical approval

The National Committee of Scientific Research approved the study (R-2016-785-074). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from all participants included in the study. Written informed consent was approved by the National Committee of Scientific Research.

References

  1. 1.
    Salloway S, Correia S (2009) Alzheimer disease: time to improve its diagnosis and treatment. Cleve Clin J Med 76(1):49–58.  https://doi.org/10.3949/ccjm.76a.072178 CrossRefPubMedGoogle Scholar
  2. 2.
    Shima K, Kuhlenbaumer G, Rupp J (2010) Chlamydia pneumoniae infection and Alzheimer’s disease: a connection to remember? Med Microbiol Immunol 199(4):283–289.  https://doi.org/10.1007/s00430-010-0162-1 CrossRefPubMedGoogle Scholar
  3. 3.
    Maheshwari P, Eslick GD (2015) Bacterial infection and Alzheimer’s disease: a meta-analysis. J Alzheimers Dis 43(3):957–966.  https://doi.org/10.3233/JAD-140621 CrossRefPubMedGoogle Scholar
  4. 4.
    Mawanda F, Wallace R (2013) Can infections cause Alzheimer’s disease? Epidemiol Rev 35:161–180.  https://doi.org/10.1093/epirev/mxs007 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Miklossy J (2011) Alzheimer’s disease—a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria. J Neuroinflamm 8:90.  https://doi.org/10.1186/1742-2094-8-90 CrossRefGoogle Scholar
  6. 6.
    Noguchi H, Moore JW (1913) A demonstration of treponema pallidum in the brain in cases of general paralysis. J Exp Med 17(2):232–238CrossRefGoogle Scholar
  7. 7.
    Adams JU (2017) Brain infection and alzheimer’s disease pathology. The Scientist. Available from: https://www.the-scientist.com/articles.view/articleNo/50212/title/Infographic--Brain-Infection-and-Alzheimer-s-Disease-Pathology/
  8. 8.
    MacDonald AB, Miranda JM (1987) Concurrent neocortical borreliosis and Alzheimer’s disease. Hum Pathol 18(7):759–761CrossRefGoogle Scholar
  9. 9.
    Riviere GR, Riviere KH, Smith KS (2002) Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer’s disease. Oral Microbiol Immunol 17(2):113–118CrossRefGoogle Scholar
  10. 10.
    Miklossy J (1993) Alzheimer’s disease—a spirochetosis? Neuro Rep 4(7):841–848Google Scholar
  11. 11.
    Gordillo-Perez G, Torres J, Solorzano-Santos F, Garduno-Bautista V, Tapia-Conyer R, Munoz O (2003) Seroepidemiologic study of Lyme’s borreliosis in Mexico City and the northeast of the Mexican Republic. Salud Publica Mex 45(5):351–355CrossRefGoogle Scholar
  12. 12.
    Gordillo-Pérez G, Solórzano-Santos F, Cervantes-Castillo A, Sánchez-Vaca G, García- Ramírez R, Mederos-Díaz Adriana et al (2019) Lyme Neuroborreliosis is a neglected, but severe and frequent neurological disease in Mexico. Arch Med Res (in press)Google Scholar
  13. 13.
    Marques AR (2015) Lyme neuroborreliosis. Contin (Minneap Minn). 21(6):1729–1744.  https://doi.org/10.1212/con.0000000000000252 (6 neuroinfectious disease) CrossRefGoogle Scholar
  14. 14.
    Koedel U, Pfister HW (2017) Lyme neuroborreliosis. Curr Opin Infect Dis 30(1):101–107.  https://doi.org/10.1097/QCO.0000000000000332 CrossRefPubMedGoogle Scholar
  15. 15.
    Sanchez JL (2015) Clinical manifestations and treatment of Lyme disease. Clin Lab Med 35(4):765–778.  https://doi.org/10.1016/j.cll.2015.08.004 CrossRefPubMedGoogle Scholar
  16. 16.
    Alby K, Capraro GA (2015) Alternatives to serologic testing for diagnosis of lyme disease. Clin Lab Med 35(4):815–825.  https://doi.org/10.1016/j.cll.2015.07.005 CrossRefPubMedGoogle Scholar
  17. 17.
    Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y et al (2015) A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol 22(12):1519–1525.  https://doi.org/10.1111/ene.12477 CrossRefPubMedGoogle Scholar
  18. 18.
    Marquard RPW, Kurz A (2012) Borrelia Burgdorferi: risk factor in Alzheimer’s disease. Eur J Neurol 19:90–457.  https://doi.org/10.1111/j.1468-1331.2012.03888.x CrossRefGoogle Scholar
  19. 19.
    Schriefer ME (2015) Lyme disease diagnosis: serology. Clin Lab Med 35(4):797–814.  https://doi.org/10.1016/j.cll.2015.08.001 CrossRefPubMedGoogle Scholar
  20. 20.
    Pearce N (2016) Analysis of matched case–control studies. BMJ 352:i969.  https://doi.org/10.1136/bmj.i969 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Niu H, Alvarez-Alvarez I, Guillen-Grima F, Aguinaga-Ontoso I (2017) Prevalence and incidence of Alzheimer’s disease in Europe: a meta-analysis. Neurologia 32(8):523–532.  https://doi.org/10.1016/j.nrl.2016.02.016 CrossRefPubMedGoogle Scholar
  22. 22.
    Carone M, Asgharian M, Jewell NP (2014) Estimating the lifetime risk of dementia in the Canadian elderly population using cross-sectional cohort survival data. J Am Stat Assoc 109(505):24–35.  https://doi.org/10.1080/01621459.2013.859076 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Romero-Martínez M, Shamah-Levy T, Franco-Núñez A, Villalpando S, Cuevas-Nasu L, Gutiérrez JP, Rivera-Dommarco JA (2013) Encuesta Nacional de Salud y Nutrición 2012: diseño y cobertura. Salud Publica Mex 55(suppl 2):S332–S340Google Scholar
  24. 24.
    Li R, Singh M (2014) Sex differences in cognitive impairment and Alzheimer’s disease. Front Neuroendocrinol 35(3):385–403.  https://doi.org/10.1016/j.yfrne.2014.01.002 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD et al (2002) Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 59(11):1737–1746CrossRefGoogle Scholar
  26. 26.
    Garkowski A, Zajkowska J, Zajkowska A, Kulakowska A, Zajkowska O, Kubas B et al (2017) Cerebrovascular manifestations of Lyme neuroborreliosis—a systematic review of published cases. Front Neurol 8:146.  https://doi.org/10.3389/fneur.2017.00146 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gordillo-Pérez G, García-Juárez I, Solórzano-Santos F, Corrales-Zúñiga L, Muñoz-Hernández O, Torres-López J (2017) Serological evidence of Borrelia Burgdorferi infection in Mexican patients with facial palsy. Rev Inves Clin 69:1–5Google Scholar
  28. 28.
    Ciudin A, Espinosa A, Simo-Servat O, Ruiz A, Alegret M, Hernandez C et al (2017) Type 2 diabetes is an independent risk factor for dementia conversion in patients with mild cognitive impairment. J Diabetes Complicat 31(8):1272–1274.  https://doi.org/10.1016/j.jdiacomp.2017.04.018 CrossRefPubMedGoogle Scholar
  29. 29.
    Marfany A, Sierra C, Camafort M, Domenech M, Coca A (2018) High blood pressure, Alzheimer disease and antihypertensive treatment. Panminerva Med 60(1):8–16.  https://doi.org/10.23736/s0031-0808.18.03360-8 CrossRefPubMedGoogle Scholar
  30. 30.
    OECD (2016) OECD reviews of health systems: Mexico 2016. OECD Publishing, ParisCrossRefGoogle Scholar
  31. 31.
    Nucera A, Hachinski V (2017) Cerebrovascular and Alzheimer disease: fellow travelers or partners in crime? J Neurochem.  https://doi.org/10.1111/jnc.14283 CrossRefGoogle Scholar
  32. 32.
    Teixeira FB, Saito MT, Matheus FC, Prediger RD, Yamada ES, Maia CSF et al (2017) Periodontitis and Alzheimer’s Disease: a possible comorbidity between oral chronic inflammatory condition and neuroinflammation. Front Aging Neurosci 9:327.  https://doi.org/10.3389/fnagi.2017.00327 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Tonsekar PP, Jiang SS, Yue G (2017) Periodontal disease, tooth loss and dementia: is there a link? A Syst Rev Gerodontol 34(2):151–163.  https://doi.org/10.1111/ger.12261 CrossRefGoogle Scholar
  34. 34.
    Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N et al (2012) Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS One 7(10):e48277.  https://doi.org/10.1371/journal.pone.0048277 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© European Geriatric Medicine Society 2019

Authors and Affiliations

  1. 1.Departamento de GeriatríaUMAE Hospital de Traumatología y Ortopedia “Lomas Verdes”, Instituto Mexicano del Seguro SocialNaucalpanMexico
  2. 2.Departamento de NeurologíaHospital de Especialidades, UMAE, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialMexico CityMexico
  3. 3.Facultad de MedicinaUniversidad Nacional Autónoma de MéxicoMexico CityMexico
  4. 4.Unidad de Investigación de Medicina Basada en EvidenciaHospital Infantil de México, Secretaria de SaludMexico CityMexico
  5. 5.Unidad de Investigación Médica en Enfermedades Infecciosas y ParasitariasHospital de Pediatría, UMAE, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro SocialMexico CityMexico

Personalised recommendations